Activity and safety of erlotinib as second- And third-line treatment in elderly patients with advanced non-small cell lung cancer: A phase II trial

Targeted Oncology

Volumn 5, Issue 4, 2010, Pages 231-235

  Rossi, David ^a   Dennetta, Donatella ^a   Ugolini, Marcello ^a   Catalano, Vincenzo ^a   Alessandroni, Paolo ^a   Giordani, Paolo ^a   Baldelli, Anna Maria ^a   Casadei, Virginia ^a   Graziano, Francesco ^a   Fedeli, S Luzi ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Elderly; Erlotinib; NSCLC

Indexed keywords

ERLOTINIB;

ADENOSQUAMOUS CARCINOMA; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; EYE TOXICITY; FEMALE; GERIATRIC PATIENT; HISTOLOGY; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SMOKING HABIT; SURVIVAL TIME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS; SMOKING; TUMOR STEM CELL ASSAY;

EID: 79952709511     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0163-4     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics. CA Cancer J Clin 57:43-66
2. Hutchins LF, Unger JM, Crowley JJ et al (1999) Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 341:2061-2067 (Pubitemid 30035956)
3. Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383-1389 (Pubitemid 46606420)
4. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of Minorenne on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72
5. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372 (Pubitemid 36395256)
6. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of doxetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
7. Fossella FV, DeVore R, Kerr R et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small-Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362 (Pubitemid 30415821)
8. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
9. Shepherd FA, Rodrigues-Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
10. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell-lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809-1818
11. Wheatley-Price P, Ding K, Seymour L et al (2008) Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:2350-2357
12. Perng RP, Yang CH, Chang GC et al (2008) High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 62:78-84
13. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207-214 (Pubitemid 11167383)
14. Gridelli C, Maione P, Illiano A et al (2007) Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced nonsmall- cell lung cancer: the MILES-2P studies. J Clin Oncol 25:4663-4669 (Pubitemid 350035327)
15. Lilenbaum RC, Herndon JE 2nd, List MA et al (2005) Singleagent versus combination chemotherapy in advanced non-smallcell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196 (Pubitemid 41702638)
16. Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128:947-957 (Pubitemid 41140531)
17. Asmis T, Ding K, Shepherd F et al (2005) Are age and comorbidity prognostic factors in the treatment of metastatic nonsmall- cell lung cancer (NSCLC): a review of a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) randomized trial. Lung Cancer 49:S85
18. Weiss GJ, Langer C, Rosell R et al (2006) Elderly patients benefit from from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small cell lung cancer. J Clin Oncol 24:4405-4411 (Pubitemid 46630978)
19. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced non-smallcell lung cancer. J Clin Oncol 26:3543-3551
20. Olayioye MA, Neve RM, Lane HA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167 (Pubitemid 30428195)